IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Decreased by Alliancebernstein L.P.

Alliancebernstein L.P. lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,239,220 shares of the company’s stock after selling 1,578,489 shares during the quarter. Alliancebernstein L.P.’s holdings in IDEXX Laboratories were worth $512,343,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. FSA Wealth Management LLC bought a new position in IDEXX Laboratories during the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories during the fourth quarter worth $30,000. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories in the fourth quarter worth $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories during the fourth quarter valued at $38,000. Finally, Crews Bank & Trust acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $41,000. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 1.6 %

Shares of IDXX stock opened at $415.87 on Monday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The firm has a market capitalization of $33.71 billion, a PE ratio of 38.98, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The stock has a fifty day moving average of $437.07 and a two-hundred day moving average of $442.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on IDXX. Morgan Stanley decreased their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, March 25th. Finally, Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.